- |
Dexamethasone Intravitreal Implant |
Ozurdex® |
Treatment of macular oedema following Retinal Vein Occlusion |
NCPE Assessment Process Complete |
16th March 2012 |
 |
- |
Dexmedetomidine |
Dexdor® |
For the treatment of ICU adult patients requiring light to moderate sedation |
Rapid Review Complete |
6th September 2011 |
 |
- |
Diclofenac |
Itami® |
For the local symptomatic and short-term treatment (max. 7 days) of pain in acute strains, sprains or bruises of the extremities following blunt trauma e.g. sports injuries in adolescents aged from 16 years and adults |
Rapid Review Complete |
17th January 2019 |
 |
- |
Dienogest |
Visanne® |
For the Treatment of Endometriosis |
Rapid Review Complete |
4th October 2010 |
 |
23001 |
Difelikefalin |
Kapruvia® |
For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis. |
Full HTA submission received from Applicant |
12th September 2023 |
 |
- |
Dimethyl fumarate |
Skilarence® |
For the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy. |
Rapid Review Complete |
6th February 2018 |
 |
- |
Dimethyl fumarate |
Tecfidera® |
For the treatment of adult patients with relapsing remitting multiple sclerosis (MS) |
NCPE Assessment Process Complete |
16th January 2015 |
 |
__ |
Dinutuximab beta |
Qarziba® |
For the treatment of high-risk neuroblastoma in patients ≥ 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease. |
NCPE Assessment Process Complete |
22nd October 2018 |
 |
21047 |
Diroximel fumarate |
Vumerity® |
For the treatment of adult patients with relapsing-remitting multiple sclerosis |
Rapid Review Complete |
16th December 2021 |
 |
- |
Dolutegravir |
Tivicay® |
In combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age. |
Rapid Review Complete |
13th March 2014 |
 |
- |
Dolutegravir/lamivudine |
Dovato® |
For the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. |
Rapid Review Complete |
27th August 2019 |
 |
- |
Dolutegravir/Rilpivirine |
Juluca® |
For the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. |
Rapid review complete |
12th July 2018 |
 |
- |
Doravirine |
Pifeltro® |
In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. |
Rapid review complete |
16th January 2019 |
 |
- |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate |
Delstrigo® |
For the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine or tenofovir |
Rapid review complete |
16th January 2019 |
 |
21045 |
Dostarlimab |
Jemperli® |
Indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. |
NCPE Assessment Process Complete |
27th March 2023 |
 |
23052 |
Doxylamine/pyridoxine |
Cariban® |
Doxylamine/pyridoxine (Cariban®) is indicated for the symptomatic treatment of nausea and vomiting during pregnancy in adults who do not respond to conservative management. |
Rapid Review Complete |
30th August 2023 |
 |
- |
Doxylamine/pyridoxine |
Xonvea® |
For the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. |
Rapid review complete |
15th August 2019 |
 |
- |
Dronedarone |
Multaq® |
__ |
Rapid review complete |
12th January 2010 |
 |
22073 |
Drospirenone/estetrol monohydrate |
Drovelis® |
Drospirenone/estetrol monohydrate is indicated for oral contraception. |
Rapid Review Complete |
6th July 2023 |
 |
- |
Dulaglutide |
Trulicity® |
As monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. Dulaglutide is indicated as an add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. |
Rapid review complete |
29th April 2015 |
 |
23047 |
Dupilumab |
Dupixent® |
Dupilumab (Dupixent®) is indicated for the treatment of adults and adolescents 12 years and older, weighing at least 40 kg, with eosinophilic oesophagitis (EoE) who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. |
Rapid Review Complete |
7th September 2023 |
 |
19056 |
Dupilumab |
Dupixent® |
For the treatment of moderate-to-severe atopic dermatitis in adolescents 12 years and older who are candidates for systemic therapy. |
Rapid review complete |
17th January 2020 |
 |
23043 |
Dupilumab |
Dupixent® |
Dupilumab (Dupixent®) is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. |
Rapid Review Complete |
24th August 2023 |
 |
23044 |
Dupilumab |
Dupixent® |
Dupilumab (Dupixent®) is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. |
Rapid Review Complete |
5th September 2023 |
 |
21063 |
Dupilumab |
Dupixent® |
For adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance. |
Rapid review complete |
8th February 2022 |
 |
21035 |
Dupilumab |
Dupixent® |
For severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy. |
Rapid review complete |
23rd September 2021 |
 |
23042 |
Dupilumab |
Dupixent® |
Dupilumab is indicated for the treatment of severe atopic dermatitis in children aged 6 months to 6 years old who are candidates for systemic therapy. |
Rapid Review Complete |
1st September 2023 |
 |
23046 |
Dupilumab |
Dupixent® |
Dupilumab (Dupixent®) is indicated as an add-on therapy with intranasal corticosteroids, for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. |
Rapid Review Complete |
5th September 2023 |
 |
- |
Dupilumab |
Dupixent® |
For treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. |
NCPE Assessment Process Complete |
12th December 2019 |
 |
- |
Durvalumab |
Imfinzi® |
For the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT). |
NCPE Assessment Process Complete |
7th May 2020 |
 |
21033 |
Durvalumab |
Imfinzi® |
In combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer. |
Rapid review complete |
9th September 2021 |
 |
23009 |
Durvalumab |
Imfinzi® |
Durvalumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer. |
Awaiting full HTA submission from Applicant |
6th June 2023 |
 |
- |
Eculizumab |
Soliris® |
For the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in the Irish healthcare setting. |
Assessment process complete |
14th October 2013 |
 |
- |
Edoxaban |
Lixiana® |
For the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults. |
Rapid review complete |
10th July 2015 |
 |
23026 |
Efgartigimod alfa |
Vyvgart® |
Efgartigimod alfa is indicated as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis who are anti-acetylcholine receptor antibody positive. |
Pre submission consultation scheduled |
12th July 2023 |
 |
22072 |
Eladocagene exuparvovec |
Upstaza® |
For the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype. |
Awaiting full HTA submission from Applicant |
23rd December 2022 |
 |
- |
Elbasvir 50mg/100mg grazoprevir |
Zepatier® |
For the treatment of genotypes 1 and 4 chronic HCV infection in patients with Child-Turcotte-Pugh score A (CTPA) |
Rapid review complete |
13th October 2016 |
 |
- |
Eliglustat |
Cerdelga® |
For the long-term treatment of adult patients with Gaucher disease type 1. |
Assessment process complete |
25th April 2018 |
 |
- |
Elosulfase alfa |
Vimzim® |
For the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome, MPS IVA) in patients of all ages. |
Assessment process complete |
8th December 2016 |
 |
- |
Eltrombopag |
Revolade® |
For the treatment of chronic immune thrombocytopenic purpura (ITP) |
Assessment process complete |
4th November 2010 |
 |
- |
Eltrombopag |
Revolade® |
For adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy |
Rapid review complete |
14th February 2014 |
 |
- |
Eltrombopag |
Revolade® |
For the treatment adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation. |
Assessment process complete |
2nd March 2016 |
 |
- |
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide |
Genvoya® |
For the treatment of adults and adolescents infected with human immunodeficiency virus – 1 (HIV-1). |
Rapid review complete |
6th January 2016 |
 |
- |
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumerate) |
Stribild® |
For the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®. |
Rapid review complete |
20th May 2013 |
 |
- |
Empagliflozin |
Jardiance® |
Add-on combination therapy: In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. |
Rapid review complete |
17th June 2014 |
 |
21030 |
Empagliflozin |
Jardiance® |
For the treatment of symptomatic chronic heart failure with reduced ejection fraction. |
Assessment process complete |
28th April 2022 |
 |
22068 |
Empagliflozin |
Jardiance® |
For the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40% |
Rapid review complete |
2nd December 2022 |
 |
- |
Emtricitabine / tenofovir disoproxil fumarate |
Truvada® |
In combination with safer sex practices for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. |
Awaiting Applicant submission |
18th July 2017 |
 |
- |
Emtricitabine/tenofovir alafenamide |
Descovy® |
In combination with other antiretroviral agents (ARVs) for the treatment of adults and adolescents (≥12 years; body weight ≥35 kg) infected with human immunodeficiency virus (HIV) type 1 |
Rapid review complete |
26th April 2016 |
 |
- |
Emtricitabine/tenofovir disoproxil |
TEVA® |
For pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk |
Rapid review complete |
22nd December 2017 |
 |